Allergy medication can affect CRP (C-reactive protein) levels in ways that are clinically important to understand. CRP is a liver-produced protein widely used across the NHS as a marker of systemic inflammation, helping clinicians assess infection, autoimmune conditions, and inflammatory disease. Certain allergy treatments — particularly systemic corticosteroids — can suppress CRP, potentially masking serious conditions such as sepsis. Others, including standard antihistamines and intranasal steroids, are unlikely to cause meaningful changes. This article explains how different allergy medicines interact with CRP, how to interpret results accurately, and when to seek medical advice.

What Is CRP and Why Is It Measured?

C-reactive protein (CRP) is a protein produced by the liver in response to inflammation anywhere in the body. When tissues are damaged, infected, or inflamed, the immune system triggers the release of signalling molecules called cytokines — particularly interleukin-6 — which stimulate the liver to produce CRP. Blood levels of CRP therefore serve as a reliable, non-specific marker of systemic inflammation and are widely used in clinical practice across the NHS.

CRP is measured through a simple blood test and reported in milligrams per litre (mg/L). In healthy adults, levels are typically below 5 mg/L, though many laboratories now use a high-sensitivity CRP (hs-CRP) assay capable of detecting lower-level chronic inflammation. Elevated CRP can indicate a broad range of conditions, including bacterial infections, autoimmune diseases, cardiovascular disease, and inflammatory conditions such as rheumatoid arthritis.

In UK primary care, CRP is used alongside clinical assessment to help guide decisions — for example, NICE antimicrobial prescribing guidance for respiratory tract infections uses the following approximate thresholds as one factor in decision-making: a CRP below 20 mg/L generally does not support antibiotic treatment; 20–100 mg/L may prompt consideration of a delayed prescription; and above 100 mg/L may support immediate antibiotic treatment. These thresholds must always be interpreted in the context of the full clinical picture.

It is important to understand that CRP is not a reliable or recommended biomarker for diagnosing or monitoring allergic disease. Specifically:

• IgE-mediated allergic reactions do not reliably produce a significant rise in CRP

• Chronic allergic inflammation (for example, in severe asthma or eosinophilic conditions) may occasionally be associated with mildly elevated levels, but CRP is not used to assess allergic disease activity

• Concurrent infections — particularly in patients on systemic corticosteroids or those with skin barrier disease such as severe atopic dermatitis — can cause more pronounced CRP elevations

Because CRP is non-specific, it must always be interpreted alongside clinical symptoms, a full medical history, and other relevant investigations. A single CRP result in isolation rarely provides a definitive diagnosis.

How Allergy Medications Can Influence CRP Levels

Several classes of allergy medication have pharmacological properties that may, directly or indirectly, influence CRP levels. Understanding these mechanisms helps both patients and clinicians interpret blood test results more accurately when allergy treatment is ongoing.

Corticosteroids are among the most potent anti-inflammatory agents used in allergy management. They work by suppressing the transcription of pro-inflammatory cytokines — including interleukin-6, a key driver of CRP production — thereby reducing hepatic CRP synthesis. It is important to distinguish between routes of administration:

• Systemic corticosteroids (oral prednisolone or parenteral hydrocortisone) have significant whole-body anti-inflammatory effects and can meaningfully suppress CRP. Patients taking systemic corticosteroids may show artificially low CRP levels even in the presence of active infection or serious inflammation. This is a clinically important consideration, as it can mask serious conditions — including sepsis. This risk is noted in the MHRA-approved product information (Summary of Product Characteristics) for prednisolone.

• Inhaled corticosteroids (ICS) such as fluticasone and intranasal corticosteroids such as mometasone, when used at standard licensed doses, have predominantly local anti-inflammatory effects. Their systemic absorption is low, and they are unlikely to cause clinically meaningful suppression of CRP in most patients. At higher doses or with prolonged use, some systemic absorption does occur, but a significant effect on CRP remains unlikely for the majority of patients.

Antihistamines — such as cetirizine, loratadine, and fexofenadine — primarily act by blocking histamine H1 receptors. There is some research interest in whether H1 antihistamines may have modest anti-inflammatory properties beyond receptor blockade; however, at standard therapeutic doses, any effect on CRP is not considered clinically significant. There is no established link between routine antihistamine use and meaningful changes in CRP, and patients should not expect their antihistamine to alter blood test results.

Leukotriene receptor antagonists such as montelukast block the action of leukotrienes — inflammatory mediators involved in asthma and allergic rhinitis. Whilst reducing leukotriene-driven inflammation is the intended mechanism, robust clinical evidence specifically linking montelukast to measurable CRP changes in allergic patients is limited. CRP is not used to guide or monitor montelukast treatment. Clinicians should always consider the patient's full medication list when reviewing CRP results.

If you experience unexpected or concerning symptoms whilst taking any allergy medicine, you can report these to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Which Allergy Treatments Are Most Likely to Affect Inflammation Markers

Not all allergy treatments carry the same potential to influence inflammatory markers such as CRP. The likelihood and magnitude of any effect depends largely on the drug class, route of administration, dose, and duration of treatment.

Systemic corticosteroids carry the greatest potential to suppress CRP. Oral prednisolone courses — prescribed for conditions such as severe allergic reactions, acute asthma exacerbations, or severe atopic dermatitis flares — can reduce CRP significantly within 24 to 48 hours of initiation. This suppression can persist for the duration of treatment and for a period after cessation, depending on the dose and length of the course. It is important to note that, in the management of anaphylaxis, current Resuscitation Council UK guidance identifies intramuscular adrenaline as the essential first-line treatment; systemic corticosteroids are not routinely recommended as part of acute anaphylaxis management.

Biological therapies used in severe allergic disease represent a growing area of relevance. Agents commissioned by NHS England and approved via NICE Technology Appraisals include:

• Dupilumab (severe atopic dermatitis and severe asthma) — targets the IL-4 and IL-13 signalling pathway

• Omalizumab (chronic spontaneous urticaria and severe allergic asthma) — targets IgE

• Mepolizumab and benralizumab (severe eosinophilic asthma) — target IL-5 or its receptor

These biologics can reduce type 2 inflammatory activity over time. However, CRP is not a standard or recommended biomarker for assessing response to biologic therapy in allergic disease. Clinically relevant monitoring markers vary by condition and may include fractional exhaled nitric oxide (FeNO), blood eosinophil count, and total IgE, as appropriate. Monitoring protocols are determined by the prescribing specialist in secondary care in line with NICE Technology Appraisal criteria.

Inhaled and intranasal corticosteroids, at standard licensed doses, have a predominantly local anti-inflammatory effect. Systemic absorption is low, and clinically meaningful suppression of CRP is unlikely for most patients. At higher doses or with prolonged use, some systemic absorption occurs, but a significant impact on CRP remains uncommon. The MHRA-approved product information for individual inhaled and intranasal corticosteroids provides further detail on systemic absorption profiles.

Interpreting CRP Results If You Take Allergy Medication

Interpreting CRP results accurately requires an understanding of the patient's full clinical picture, including any allergy medications they are currently taking. A result that appears reassuringly normal may, in some circumstances, be falsely low due to the anti-inflammatory effects of treatment — particularly systemic corticosteroids. This is especially important when infection or sepsis is being considered.

Conversely, a mildly elevated CRP in a patient with known allergic disease does not automatically indicate a new or serious pathology. Possible explanations include:

• Intercurrent infection — respiratory infections and skin infections (for example, in patients with atopic dermatitis and impaired skin barrier function) can cause significant CRP rises, particularly in those on systemic corticosteroids or high-dose ICS

• Active inflammatory disease — poorly controlled asthma, severe atopic dermatitis, or eosinophilic conditions may occasionally be associated with mildly elevated CRP, though CRP is not a reliable marker of allergic disease activity

• Unrelated inflammatory conditions — CRP is non-specific and may reflect pathology entirely unrelated to allergy

Note that acute IgE-mediated allergic reactions do not reliably elevate CRP, and CRP should not be used to confirm or exclude an allergic reaction.

Healthcare professionals reviewing CRP in patients on allergy medication should always document current treatments, doses, and duration. It is good practice to note on the laboratory request whether a patient is mid-course of oral steroids at the time of blood testing, as this context is essential for accurate interpretation.

Red-flag symptoms requiring urgent assessment — including fever with rigors, severe breathlessness, chest pain, confusion, hypotension, or a rapidly spreading rash — should prompt same-day medical review regardless of CRP level. If you are concerned about any of these symptoms, contact your GP urgently, call NHS 111, or dial 999 in an emergency.

Patients should be encouraged to inform their GP or practice nurse of all allergy medications — including over-the-counter antihistamines and any recent steroid courses — before or at the time of blood tests. This transparency supports safer, more accurate clinical decision-making and avoids unnecessary further investigation based on a misinterpreted result.

When to Speak to a GP About Your CRP and Allergy Treatment

Most people taking standard allergy medications such as antihistamines or intranasal steroids will not need to routinely monitor their CRP. However, there are specific circumstances in which it is important to seek medical advice about CRP results in the context of allergy treatment.

Contact your GP if:

• Your CRP is elevated — particularly above 20 mg/L — without an obvious explanation such as a known infection; your GP will interpret this alongside your symptoms and clinical history in line with NICE guidance

• You have been prescribed repeated or prolonged courses of oral corticosteroids and are experiencing new or unexplained symptoms

• You are taking a biologic therapy for severe allergic disease and your condition is worsening or you develop new symptoms

• You have symptoms suggestive of infection — such as fever, productive cough, or purulent discharge — alongside a raised CRP; if you are taking systemic corticosteroids, these medicines can mask the clinical severity of infection, so prompt review is important

• Your allergy symptoms are worsening despite treatment and blood tests suggest ongoing systemic inflammation

Seek same-day urgent medical assessment (via your GP, urgent treatment centre, or NHS 111) if you have a raised CRP alongside systemic symptoms such as high fever, rigors, or feeling very unwell. Call 999 immediately if you experience severe breathlessness, chest pain, confusion, loss of consciousness, or signs of anaphylaxis.

Patients on systemic corticosteroids or high-dose inhaled corticosteroids may be at increased risk of infections, and infections may present atypically in this group. A raised CRP in these individuals warrants prompt clinical assessment rather than a 'watch and wait' approach.

If you are unsure whether your allergy medication could be affecting your blood test results, raise this with your GP or allergy specialist. Shared decision-making and open communication between patient and clinician are central to safe allergy management.

You can also report any suspected side effects from your allergy medicines to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

NHS Guidance on Allergy Management and Blood Test Monitoring

The NHS and relevant clinical bodies provide clear frameworks for the investigation and management of allergic conditions, within which blood test monitoring — including CRP — plays a supporting but context-dependent role.

Key UK clinical guidance includes:

• NICE NG80 (Asthma: diagnosis, monitoring and chronic asthma management) and the BTS/SIGN British Guideline on the Management of Asthma both provide widely used frameworks for asthma care in the UK, including the role of biomarkers such as FeNO and blood eosinophils. CRP is not a recommended routine monitoring marker for asthma.

• NICE CG57 (Atopic eczema in under 12s) and updated NICE guidance on atopic dermatitis provide stepwise treatment frameworks. Blood tests including inflammatory markers may support diagnosis or assessment of complications but are not used for routine surveillance in stable disease.

• For chronic spontaneous urticaria, the BSACI guideline on urticaria and angioedema is the primary UK specialty reference, alongside relevant NICE Technology Appraisals (for example, for omalizumab). There is no comprehensive NICE clinical guideline for chronic urticaria management.

• Resuscitation Council UK Anaphylaxis Guidelines define the current UK standard for anaphylaxis management, with intramuscular adrenaline as the essential first-line treatment.

For patients prescribed systemic corticosteroids, NHS guidance and MHRA-approved product information highlight the risks of adrenal suppression, immunosuppression, and atypical presentation of infections. A normal or low CRP should not be taken as definitive reassurance if clinical symptoms suggest infection in a patient taking systemic steroids.

The MHRA and EMA product information for biologic therapies — such as dupilumab, omalizumab, mepolizumab, and benralizumab — advise regular clinical review; specific CRP monitoring thresholds are not universally mandated, and monitoring protocols are determined by the prescribing specialist in secondary care in line with NICE Technology Appraisal criteria.

Key practical points aligned with NHS and UK clinical guidance:

• Always inform your healthcare team of all allergy medications before blood tests, including over-the-counter antihistamines and any recent steroid courses

• Do not stop prescribed allergy medication before a blood test without medical advice, as this may destabilise your condition

• Follow up abnormal CRP results with your GP, particularly if you are on immunosuppressive therapy

• Access NHS allergy services via GP referral if your condition is poorly controlled or if blood test results are persistently abnormal

• Report suspected side effects from any allergy medicine to the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk

For further information, patients and clinicians can refer to the NHS website (nhs.uk), NICE Evidence (nice.org.uk), the BSACI (bsaci.org), and Allergy UK (allergyuk.org), which provide up-to-date, evidence-based resources on allergy diagnosis and treatment.

Frequently Asked Questions